Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzenesulfonamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 16/20 | 0.89 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.52 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 14/20 | 0.89 |
| ▸ | CA12 | O43570 | 13/20 | 0.89 |
| ▸ | CA9 | Q16790 | 13/20 | 0.89 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.89 |
| ▸ | CA4 | P22748 | 3/20 | 0.89 |
| ▸ | CA6 | P23280 | 3/20 | 0.89 |
| ▸ | CA5A | P35218 | 3/20 | 0.89 |
| ▸ | CA7 | P43166 | 3/20 | 0.89 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.89 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.89 |
| ▸ | CA3 | P07451 | 2/20 | 0.89 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.89 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenesulfonamide SCHEMBL6999082 | 0.97 | CA2 (0.94) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL861258 | 0.97 | CA2 (0.94) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL1009443 | 0.97 | CA2 (0.94) | CA2CA1CA12CA9CA14 | |
| SCHEMBL19479299 | 0.94 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL29825137 | 0.94 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL28257999 | 0.94 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL1332409 | 0.94 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL729 | 0.94 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL6868390 | 0.94 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Benzenesulfonamide SCHEMBL3056735 | 0.92 | CA2 (0.94) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103282036-A | Compositions and methods for treating myelofibrosis | TARGEGEN INC | 2013-09-04 | — | — | CN | claimed |
| CN-116829136-A | Administration of phenanthroline tinib | 生物医学影响公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-2635282-B1 | COMPOSITIONS FOR TREATING MYELOFIBROSIS | IMPACT BIOMEDICINES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-108125923-A | For treating the composition of myelofibrosis and method | 生物医学影响公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-103282036-B | compositions and methods for treating myelofibrosis | 塔格根公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-103282036-A | Compositions and methods for treating myelofibrosis | TARGEGEN INC | 2013-09-04 | — | — | CN | disclosed |